Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819228 | 1.00 | KMT2A (0.64) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL5174096 | 1.00 | KMT2A (0.64) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL17856541 | 1.00 | KMT2A (0.64) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL18425978 | 0.82 | KMT2A (0.61) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL274251 | 0.82 | KMT2A (0.61) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL15167694 | 0.82 | KMT2A (0.60) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL631726 | 0.82 | KMT2A (0.60) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL527800 | 0.82 | KMT2A (0.60) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL274179 | 0.80 | TDO2 (0.53) | KMT2AALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL21546057 | 0.80 | CAPN1 (0.56) | KMT2AALDH1A1GAAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683535-B | Compound containing cyanoguanidine structure and preparation method and application thereof | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-113683535-A | Compound containing cyanoguanidine structure and preparation method and application thereof | 中国药科大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| EP-3328379-B1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| US-10975066-B2 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-04-13 | — | — | US | disclosed |
| US-20200123512-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-04-23 | — | — | US | disclosed |
| US-10544402-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180222899-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3328379-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SPRL (BE) | 2018-06-06 | — | — | EP | disclosed |
| EP-2828385-B1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | CODEXIS INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170283781-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-10-05 | — | — | US | disclosed |
| US-9708588-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017020010-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20160289649-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-10-06 | — | — | US | disclosed |
| US-9388395-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150344854-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-12-03 | — | — | US | disclosed |
| US-9139821-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150072383-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-03-12 | — | — | US | disclosed |
| WO-2009104198-A2 | METAL CONJUGATES OF INDOLE 3- ALDEHYDE AZINE AND ITS DERIVATIVES AND USES THEREOF | VLIFE SCIENCES TECHNOLOGIES PVT. LTD. (IN) | 2009-08-27 | — | — | WO | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975066-B2 | Bis-heteroaryl derivatives as modulators of protein aggregation | HTT, PARK7, SNCA | KMT2A 1383/4885ALDH1A1 4670/4885GAA 973/4885 |
| US-20180222899-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | HTT, PARK7, SNCA | KMT2A 1383/4885ALDH1A1 4670/4885GAA 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.